What Enbrel needs to do after its patent win
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
Mylan gets an injection, administered by Pfizer
The combination of Upjohn and Mylan means that, for a change, Pfizer is getting smaller. But will the company’s new chief executive really be able to resist the urge to…
Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
A Nasdaq float is scrapped, but for Poseida that’s great news
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Roche dominates 2019’s big patent expiries
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
Boston and Edwards make a smart judgement
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Medtech news over the Christmas period
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.